Market revenue in 2023 | USD 6,564.3 million |
Market revenue in 2030 | USD 10,676.4 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Clinical chemistry |
Fastest growing segment | Medical Microbiology & Cytology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Tests |
Key market players worldwide | Labcorp Holdings Inc, Qiagen NV, Eurofins Scientific SE, Quest Diagnostics Inc, OPKO Health Inc, Siemens Healthineers AG ADR, NeoGenomics Inc, Fresenius Medical Care AG, Sonic Healthcare Ltd, Charles River Laboratories International Inc, SYNLAB Group, Mayo Clinic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical laboratory service market will help companies and investors design strategic landscapes.
Clinical chemistry was the largest segment with a revenue share of 45.98% in 2023. Horizon Databook has segmented the Japan clinical laboratory service market based on human & tumor genetics, clinical chemistry, medical microbiology & cytology, other esoteric tests covering the revenue growth of each sub-segment from 2018 to 2030.
Geographic expansion strategies undertaken in the Asia Pacific market by major U.S.-based players to strengthen their position are anticipated to drive market growth in Japan. For instance, in June 2022, LabCorp expanded its central laboratory presence and drug development capabilities in Japan through an expansion of the CB Trial Laboratory.
Such expansions are likely to boost the market in Japan The market is expected to grow at a steady rate in the coming years due to the varying requirement of tests, which is mostly based on physicians’ demand for tests.
The MHLW Japan controls the reimbursement scenario in Japan. Japan launched a modernized list of reimbursement prices, along with devices and tests that are reimbursed. Most of the tests are performed in hospitals; over 50% of the clinical testing market is hospital-based.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan clinical laboratory service market , including forecasts for subscribers. This country databook contains high-level insights into Japan clinical laboratory service market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account